|
1
|
Chen X, Kuang S, He Y, Li H, Yi C, Li Y, Wang C, Chen G, Chen S, Yu D. The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure. Metabolites 2022; 12:metabo12050389. [PMID: 35629893 PMCID: PMC9147301 DOI: 10.3390/metabo12050389] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 04/18/2022] [Accepted: 04/22/2022] [Indexed: 01/27/2023] Open
Abstract
Metabolic reprogramming is one of the hallmarks of a tumor. It not only promotes the development and progression of tumor but also contributes to the resistance of tumor cells to chemotherapeutics. The difference in the metabolism between drug-resistant and sensitive tumor cells indicates that drug-resistant tumor cells have experienced metabolic adaptation. The metabolic response induced by chemotherapy is dynamic, but the early metabolic response of tumor cells to anticancer drugs and the effect of an initial response on the development of drug resistance have not been well studied. Early metabolic intervention may prevent or slow down the development of drug resistance. The differential metabolic responses of normal cells and tumor cells to drugs are unclear. The specific metabolites or metabolic pathways of tumor cells to chemotherapeutic drugs can be used as the target of metabolic intervention in tumor therapy. In this study, we used comparative metabolomics to analyze the differential metabolic responses of oral cancer cells and normal oral epithelial cells to short-term cisplatin exposure, and to identify the marker metabolites of early response in oral cancer cells. Oral cancer cells showed a dynamic metabolic response to cisplatin. Seven and five metabolites were identified as specific response markers to cisplatin exposure in oral cancer cell SCC-9 and normal oral epithelial cell HOEC, respectively. Glyoxylate and dicarboxylate metabolism and fructose, malate, serine, alanine, sorbose and glutamate were considered as specific enriched metabolic pathways and biomarkers of SCC-9 cells in response to cisplatin, respectively. The existence of differential metabolic responses lays a foundation for tumor chemotherapy combined with metabolic intervention.
Collapse
Affiliation(s)
- Xun Chen
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Sufang Kuang
- Center for Proteomics and Metabolomics, State Key Laboratory of Biocontrol, Guangdong Province Key Laboratory for Pharmaceutical Functional Genes, School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China;
| | - Yi He
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Hongyu Li
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Chen Yi
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Yiming Li
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Chao Wang
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Guanhui Chen
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
| | - Shangwu Chen
- Guangdong Key Laboratory of Pharmaceutical Functional Genes, State Key Laboratory for Biocontrol, Department of Biochemistry, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China
- Correspondence: (S.C.); (D.Y.); Tel.: +86-20-3933-2990 (S.C.); +86-20-8386-2543 (D.Y.)
| | - Dongsheng Yu
- Hospital of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; (X.C.); (Y.H.); (H.L.); (C.Y.); (Y.L.); (C.W.); (G.C.)
- Correspondence: (S.C.); (D.Y.); Tel.: +86-20-3933-2990 (S.C.); +86-20-8386-2543 (D.Y.)
| |
Collapse
|
|
2
|
Metabolic Reprogramming of Chemoresistant Cancer Cells and the Potential Significance of Metabolic Regulation in the Reversal of Cancer Chemoresistance. Metabolites 2020; 10:metabo10070289. [PMID: 32708822 PMCID: PMC7408410 DOI: 10.3390/metabo10070289] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 06/15/2020] [Accepted: 07/04/2020] [Indexed: 02/07/2023] Open
Abstract
Metabolic reprogramming is one of the hallmarks of tumors. Alterations of cellular metabolism not only contribute to tumor development, but also mediate the resistance of tumor cells to antitumor drugs. The metabolic response of tumor cells to various chemotherapy drugs can be analyzed by metabolomics. Although cancer cells have experienced metabolic reprogramming, the metabolism of drug resistant cancer cells has been further modified. Metabolic adaptations of drug resistant cells to chemotherapeutics involve redox, lipid metabolism, bioenergetics, glycolysis, polyamine synthesis and so on. The proposed metabolic mechanisms of drug resistance include the increase of glucose and glutamine demand, active pathways of glutaminolysis and glycolysis, promotion of NADPH from the pentose phosphate pathway, adaptive mitochondrial reprogramming, activation of fatty acid oxidation, and up-regulation of ornithine decarboxylase for polyamine production. Several genes are associated with metabolic reprogramming and drug resistance. Intervening regulatory points described above or targeting key genes in several important metabolic pathways may restore cell sensitivity to chemotherapy. This paper reviews the metabolic changes of tumor cells during the development of chemoresistance and discusses the potential of reversing chemoresistance by metabolic regulation.
Collapse
|
|
3
|
Sun H, Piao H, Qi H, Yan M, Liu H. [Study on the Metabolic Reprogramming of Lung Cancer Cells Regulated by Docetaxel Based on Metabolomics]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2019; 22:208-215. [PMID: 31014438 PMCID: PMC6500501 DOI: 10.3779/j.issn.1009-3419.2019.04.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
背景与目的 多西他赛是一种临床常用的抗肿瘤药物，是晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的一线用药。然而，多西他赛抗NSCLC作用的分子机制尚不明确。研究表明肿瘤细胞的代谢重编程在肿瘤发生发展过程中发挥重要作用。本研究旨在通过结合代谢组学分析及生物学手段来探讨多西他赛所影响的NSCLC细胞代谢通路。 方法 首先，通过CCK-8实验分析多西他赛对NSCLC细胞活力的影响，筛选合适药物浓度。接下来，通过基于气相色谱质谱联用（gas chromatography-mass spectrometry, GC-MS）的代谢组学技术分析多西他赛处理和未处理的A549和H1299细胞。并通过统计学计算得到处理组和未处理组间的差异代谢物。最后，通过蛋白质免疫印迹分析（Western blot）多西他赛对其所调控的相关代谢途径中关键酶蛋白质表达水平的影响。 结果 多西他赛可时间依赖和浓度依赖地抑制A549和H1299细胞活力。随着多西他赛处理时间延长，凋亡敏感蛋白质多聚二磷酸腺苷核糖聚合酶[Poly(ADP-)Polymerase, PARP]逐渐被激活裂解形成P89片段。代谢组学分析发现，药物处理后的A549和H1299细胞内，8种代谢物均发生显著变化，主要集中于三羧酸（tricarboxylic acid, TCA）循环代谢通路。同时，药物处理后，TCA循环关键调控酶异柠檬酸脱氢酶蛋白质表达水平显著下降。 结论 多西他赛诱导NSCLC增殖抑制及凋亡的效应可能与下调异柠檬酸脱氢酶，进而抑制三羧酸循环代谢途径有关。
Collapse
Affiliation(s)
- Haichao Sun
- Department of Thoracic Surgery, Cancer Hospital, China Medical University, Shenyang 110042, China
| | - Hailong Piao
- Department of Thoracic Surgery, Cancer Hospital, China Medical University, Shenyang 110042, China
| | - Huan Qi
- Department of Thoracic Surgery, Cancer Hospital, China Medical University, Shenyang 110042, China
| | - Min Yan
- Department of Thoracic Surgery, Cancer Hospital, China Medical University, Shenyang 110042, China
| | - Hongxu Liu
- Department of Thoracic Surgery, Cancer Hospital, China Medical University, Shenyang 110042, China
| |
Collapse
|